NervGen names interim replacements for departing Paul Brennan

26 September 2022
bill_radvak_large

Shares in Canada’s NervGen Pharma (TSX-V: NGEN) closed 8% lower after trading on Friday.

NervGen earlier announced that the board of directors and Paul Brennan have mutually agreed that Mr Brennan will step down as president and chief executive and a member of the board, effective immediately.

"Paul has helped position NervGen to become a leading player in the emerging central nervous system repair field"Mr Brennan had been in the role for less than three years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical